CG
OCUL icon

Cutler Group’s Ocular Therapeutix OCUL Stock Holding History

Cutler Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,500
Closed -$5K – 4543
2018
Q4 		$5K Hold
1,500
– – ﹤0.01% 2934
2018
Q3 		$10K Hold
1,500
– – ﹤0.01% 2662
2018
Q2 		$10K Hold
1,500
– – ﹤0.01% 2679
2018
Q1 		$9K Sell
1,500
-1,013
-40% -$5.7K ﹤0.01% 2868
2017
Q4 		$11K Buy
2,513
+513
+26% +$2.62K ﹤0.01% 3056
2017
Q3 		$12K Sell
2,000
-6,341
-76% -$40.8K ﹤0.01% 3638
2017
Q2 		$77K Sell
8,341
-11,906
-59% -$115K ﹤0.01% 2088
2017
Q1 		$187K Sell
20,247
-16,297
-45% -$136K 0.01% 1244
2016
Q4 		$305K Buy
36,544
+15,641
+75% +$121K 0.01% 1011
2016
Q3 		$143K Buy
20,903
+19,403
+1,294% +$118K 0.01% 1501
2016
Q2 		$7K Buy
1,500
+700
+88% +$6.93K ﹤0.01% 4594
2016
Q1 		$7K Buy
+800
New +$6.06K ﹤0.01% 4499

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Cutler Group's OCUL Position: Q1 2019 in Review

Cutler Group sold out of Ocular Therapeutix (OCUL) in Q1 2019, closing a stake of 1,500 shares — an estimated $5K sold.

Cutler Group first reported a position in OCUL in Q1 2016 and held it in 12 quarters. The position peaked at $305K in Q4 2016. 68 funds tracked by Wall St. Rank hold OCUL as of Q1 2019.

  • Cutler Group reported no remaining Ocular Therapeutix position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 1,500 Ocular Therapeutix shares in Q1 2019, an estimated $5K.
  • Cutler Group first reported a position in Ocular Therapeutix in Q1 2016 and held it in 12 quarters.
  • Cutler Group's Ocular Therapeutix position peaked at $305K in Q4 2016.
  • 68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.